DENVER, Nov. 03, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of a technology patent that allows for the creation of formulations that utilize nanoemulsion technology to…


Previous articleU.S. FDA Approves Nova Mentis Orphan Drug Application
Next articleCOMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder